Cargando…

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities. Methods: In the current study, a network met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pei, Fajun, Yu, Yang, Dong, Bin, Guan, Hui, Dong, Xinzhe, Zhao, Fen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635017/ https://www.ncbi.nlm.nih.gov/pubmed/34867316 http://dx.doi.org/10.3389/fphar.2021.694545

Ejemplares similares

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
por: Qu, Hong-Chen, et al.
Publicado: (2020)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma
por: Cocorocchio, E, et al.
Publicado: (2010)

Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease
por: Lüke, Florian, et al.
Publicado: (2021)

Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis
por: Zhang, Xiaoping, et al.
Publicado: (2017)

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma
por: Ansell, Stephen M.
Publicado: (2017)

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer
por: Yang, Qian-Yu, et al.
Publicado: (2022)

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity
por: Barrett, Aisling, et al.
Publicado: (2023)

Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens
por: Ahmadzadeh, Ahmad, et al.
Publicado: (2014)

Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities
por: Mancini, Maria L., et al.
Publicado: (2014)

ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy
por: Jayabose, Somasundaram, et al.
Publicado: (2016)

Predictive model of chemotherapy-related toxicity in elderly Chinese cancer patients
por: Hua, Yuwei, et al.
Publicado: (2023)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
por: Tong, Xiwen, et al.
Publicado: (2023)

Current advances in Hodgkin’s lymphoma
por: Vadakara, Joseph, et al.
Publicado: (2019)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
por: Al-Mahayri, Zeina N., et al.
Publicado: (2020)

Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
por: Yokose, N., et al.
Publicado: (1998)

PB2255: ASSESSMENT OF CHEMOTHERAPY-INDUCED TOXICITY IN CHILDREN WITH HODGKIN LYMPHOMA RECEIVING THE EURONET PROTOCOL
por: Bekhit, Hala, et al.
Publicado: (2023)

Multiple Comparisons of the Efficacy and Safety for Seven Treatments in Tibia Shaft Fracture Patients
por: Li, Haibo, et al.
Publicado: (2019)

Sarcoid Reactions after Chemotherapy for Hodgkin’s Lymphoma
por: Wirk, Baldeep
Publicado: (2010)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
por: Musso, Maurizio, et al.
Publicado: (2015)

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
por: Gutierrez, Antonio, et al.
Publicado: (2014)

Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes
por: Castagna, Luca, et al.
Publicado: (2020)

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
por: Amin, M. S. A., et al.
Publicado: (2020)

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran
por: Hatam, Nahid, et al.
Publicado: (2015)

Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer
por: Wu, Dong-Mei, et al.
Publicado: (2017)

Comparative efficacy of different chemotherapies for non-Hodgkin lymphoma: a network-meta analysis
por: Cai, Pengcheng, et al.
Publicado: (2017)

Hypotension Associated with Advanced Hodgkin Lymphoma
por: Mangla, Ankit, et al.
Publicado: (2014)

Recent advances in the management of Hodgkin lymphoma
por: Villasboas, Jose C., et al.
Publicado: (2016)

Managing advanced stage Hodgkin lymphoma
por: Saikia, TK
Publicado: (2015)

Editorial: Advances in the treatment of Hodgkin lymphoma
por: Mei, Matthew, et al.
Publicado: (2023)

Advances in the treatment of Hodgkin's lymphoma (Review)
por: Che, Yuxuan, et al.
Publicado: (2023)

A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer
por: Zhang, Xiao-Hua, et al.
Publicado: (2016)

Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen.
por: Sonneveld, P., et al.
Publicado: (1990)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pdcl1p2a6b2dv3dr7t7c2brh91